1. Home
  2. IPDN vs APM Comparison

IPDN vs APM Comparison

Compare IPDN & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Professional Diversity Network Inc.

IPDN

Professional Diversity Network Inc.

N/A

Current Price

$0.59

Market Cap

6.6M

Sector

Technology

ML Signal

N/A

Logo Aptorum Group Limited

APM

Aptorum Group Limited

HOLD

Current Price

$0.79

Market Cap

6.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IPDN
APM
Founded
2003
2010
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6M
6.8M
IPO Year
2012
2018

Fundamental Metrics

Financial Performance
Metric
IPDN
APM
Price
$0.59
$0.79
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
43.5K
85.5K
Earning Date
05-15-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$22,054,219.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.65
52 Week High
$12.39
$4.47

Technical Indicators

Market Signals
Indicator
IPDN
APM
Relative Strength Index (RSI) 43.08 41.18
Support Level $0.57 $0.75
Resistance Level $0.75 $0.89
Average True Range (ATR) 0.06 0.05
MACD 0.01 -0.01
Stochastic Oscillator 39.81 14.40

Price Performance

Historical Comparison
IPDN
APM

About IPDN Professional Diversity Network Inc.

Professional Diversity Network Inc provides access to networking, training, educational, and employment services to its registered users. It has three operating segments: the TalentAlly Network segment, which maintains and operates job board software and hosts career fairs; the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization; the RemoteMore segment; and Corporate Overhead. The company generates the majority of its revenue from the TalentAlly Network Segment.

About APM Aptorum Group Limited

Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.

Share on Social Networks: